Skip to content

Study · Animal study (in vivo) · rat · 2026

3 results

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.

Alhalabi H, Borschel L, Le Foll C, Thomas A, Bally L, Thevis M

Journal of pharmaceutical and biomedical analysis13 Feb 2026

PMID41702251 (opens in a new tab)DOI10.1016/j.jpba.2026.117418 (opens in a new tab)PepBankPUB-41702251
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats given cagrilintide, metabolites predicted from in vitro experiments were observed in plasma samples.

    In plain wordsIn rats given cagrilintide, the breakdown products seen in lab tests were also found in blood plasma.

    Peptide
    Cagrilintide
    Outcome
    Not applicableCagrilintide metabolites in rat plasma
    Study

    ratn: not reported in source

    Authentic post-administration rat plasma
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cagrilintide metabolites predicted from in vitro experiments were observed in authentic post administration rat plasma samples, confirming in vivo relevance.
    1 context sentence
    Summary · context
    For comparison, authentic post-administration rat samples were analysed for cagrilintide and respective biotransformation products.
  2. 02LabIn vitro (cell-free)Pharmacokinetics

    In human skin and kidney S9 fractions and biological fluids, cagrilintide (with pramlintide and KBP-066) underwent N-terminal and C-terminal degradation, giving several stable metabolic products.

    In plain wordsIn lab tests, cagrilintide broke down from both ends, leaving several stable products that could serve as detection targets.

    Peptide
    Cagrilintide
    Outcome
    Not applicableIn vitro metabolites of cagrilintide
    Study

    humann: not reported in source

    Human skin S9 fraction, kidney S9 fraction and biological fluids
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All three peptides underwent N-terminal and C-terminal degradation, yielding multiple stable metabolic products suitable as detection targets.
    1 context sentence
    Summary · context
    Comprehensive in vitro models, including human skin S9 fraction, kidney S9 fraction and biological fluids, were used to investigate metabolic pathways.

Studies that did not test the peptide alone1

In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cagrilintide.

  1. 03LabNot a test of Cagrilintide aloneOther designOther

    Suitable preparation and detection methods for amylin receptor agonists including cagrilintide were established and validated.

    In plain wordsIn lab work, researchers set up and checked a method to detect cagrilintide and related drugs.

    Peptide
    Cagrilintide
    Outcome
    Not applicablePreparation and LC-MS/MS detection methods
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Finally, suitable preparation and detection methods were established and validated.
    1 context sentence
    Summary · context
    This study aimed to characterize the metabolic profiles of pramlintide, cagrilintide and KBP-066, identify analytically suitable metabolites and develop and validate a LC-MS/MS-based detection approach.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 34 to 39Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:25 UTC. The status did not change between them.

    Study results updated

  2. Version 33

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Versions 3 to 32

    21 Oct 2026, 17:06 UTC

    The same notice was added 30 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  4. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.